Meda Aktiebolag (publ) applies for delisting and convenes an extraordinary general meeting
Mylan N.V.s public offer for Meda Aktiebolag (publ) (“Meda”) was declared unconditional today on August 2, 2016. Mylan N.V. controls more than 90 per cent of the shares in Meda and intends to request compulsory acquisition in respect of the shares in Meda that Mylan N.V. does not own.
As requested by Mylan N.V., the Board of Meda has today convened an Extraordinary General Meeting to be held on August 25, 2016, for the purposes of, amongst other things, appointing a new board.
Further, at the request of Mylan N.V. the Board of Meda has resolved to apply for delisting of the Company’s shares from Nasdaq Stockholm (“Nasdaq”). The last day of trading in the Company’s shares on Nasdaq will be announced as soon as Meda has received confirmation from Nasdaq.
Solna, Sweden, August 2016
The board of directors
Meda AB (publ)
For further inquiries, please contact:
Paula Treutiger, VP Corporate Communications & Sustainability ph: +46 733-666 599 firstname.lastname@example.org
This information is information that Meda AB is obliged to make public pursuant to the EU Market Abuse Regulation. The above information was submitted for publication, through the agency of the contact person set out above, 17:15 p.m. CET on 2 August 2016.
MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in more than 150 countries worldwide and the company is represented by its own organizations in over 60 countries. The Meda share is listed under Large Cap on Nasdaq Stockholm. Find out more, visit www.meda.se.